Journal article
External Validation of a Tool Predicting 7-Year Risk of Developing Cardiovascular Disease, Type 2 Diabetes or Chronic Kidney Disease
SP Rauh, F Rutters, AAWA van der Heijden, T Luimes, M Alssema, MW Heymans, DJ Magliano, JE Shaw, JW Beulens, JM Dekker
Journal of General Internal Medicine | SPRINGER | Published : 2018
Abstract
Background: Chronic cardiometabolic diseases, including cardiovascular disease (CVD), type 2 diabetes (T2D) and chronic kidney disease (CKD), share many modifiable risk factors and can be prevented using combined prevention programs. Valid risk prediction tools are needed to accurately identify individuals at risk. Objective: We aimed to validate a previously developed non-invasive risk prediction tool for predicting the combined 7-year-risk for chronic cardiometabolic diseases. Design: The previously developed tool is stratified for sex and contains the predictors age, BMI, waist circumference, use of antihypertensives, smoking, family history of myocardial infarction/stroke, and family his..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Also, for funding or logistical support, we are grateful to the National Health and Medical Research Council (NHMRC grants 233200 and 1007544), Australian Federal Department of Health and Ageing, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd., Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services-Northern Territory, Department of Health and Human Services-Tasmania, Department of Health-New South Wales, Department of Health-Western Australia, Department of Health-South Australia, Department of Human Services-Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, The Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, The Marian & E.H. Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd., Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital-Sydney, Sanofi Aventis, Sanofi-Synthelabo, and the Victorian Government OIS Program.